TI
ESPR icon

Turner Investments’s Esperion Therapeutics ESPR Stock Holding History

Turner Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-17,560
Closed -$1.44M – 260
2015
Q2 		$1.44M Buy
+17,560
New +$1.72M 0.26% 127

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Turner Investments's ESPR Position: Q3 2015 in Review

Turner Investments sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 17,560 shares — an estimated $1.44M sold.

Turner Investments first reported a position in ESPR in Q2 2015 and held it in 1 quarter. The position peaked at $1.44M in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

  • Turner Investments reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Turner Investments sold 17,560 Esperion Therapeutics shares in Q3 2015, an estimated $1.44M.
  • Turner Investments first reported a position in Esperion Therapeutics in Q2 2015 and held it in 1 quarter.
  • Turner Investments's Esperion Therapeutics position peaked at $1.44M in Q2 2015.
  • 121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on Turner Investments's 13F filing for Q3 2015, filed 12 Nov 2015.